Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Gold Nanoparticle-Based Test Better for Prostate Cancer Diagnosis Than PSA

By LabMedica International staff writers
Posted on 13 Apr 2015
A rapid and simple gold nanoparticle-based blood test proved better at diagnosing prostate cancer than did the commonly used PSA (prostate-specific antigen) assay.

Investigators at the University of Central Florida (Orlando, USA) based their NanoDLSay test on the ability of gold nanoparticles to bind certain proteins from the serum and to increase in size and change their light scattering properties.

When citrate ligands-capped gold nanoparticles are mixed with blood sera, a protein corona is formed on the nanoparticle surface due to the adsorption of various proteins in the blood to the nanoparticles. More...
Using a two-step gold nanoparticle-enabled dynamic light scattering assay, the investigators discovered that the amount of human immunoglobulin G (IgG) in the gold nanoparticle protein corona was increased in prostate cancer patients compared to healthy controls. Two pilot studies conducted on blood serum samples collected at Florida Hospital (USA) and obtained from the Prostate Cancer Biorespository Network revealed that the test had 90%–95% specificity and 50% sensitivity in detecting early stage prostate cancer, representing a significant improvement over the current PSA test.

The investigators postulated that the increased amount of human IgG found in the protein corona was associated with the autoantibodies produced in cancer patients as part of the immune system's defense against the tumor. Proteomic analysis of the nanoparticle protein corona revealed molecular profile differences between serum samples from cancer patients and healthy individuals. Autoantibodies and natural antibodies produced in cancer patients in response to tumorigenesis have been found and detected in the blood of many cancer types. Thus, the test may be applicable for early detection and risk assessment of a broad spectrum of cancer types.

"What is different and unique about our technique is it is a very simple process, and the material required for the test is less than one USD," said senior author Dr. Qun Huo, professor of chemistry at the University of Central Florida. "And because it is low-cost, we are hoping most people can have this test in their doctor's office. If we can catch this cancer in its early stages, the impact is going to be big."

The investigators have founded the biomedical company Nano Discovery Inc. (Orlando, FL, USA) to commercialize the NanoDLSay diagnostic test for prostate cancer.

The report was published in the March 10, 2015, online edition of the journal ACS Applied Materials & Interfaces.

Related Links:
University of Central Florida
Nano Discovery Inc.



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.